Roche’s virtual event on key Evrysdi data presented at the 2021 CureSMA Annual Meeting
Roche has hosted a virtual event on Monday, 14th June 2021.
| Agenda | |
|---|---|
| JEWELFISH | Safety, pharmacodynamic and exploratory efficacy data in non-naïve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam |
| RAINBOWFISH | A study of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA) Kathryn Wagner, M.D. Ph.D., Vice President of Neuromuscular Disorders Clinical Development |
| Q&A | Kathryn Wagner, M.D. Ph.D., Vice President of Neuromuscular Disorders Clinical Development Paulo Fontoura, M.D. Ph.D., Global Head of Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases Clinical Development Simona Skerjanec, Therapeutic Area Head Neuroscience and Rare Diseases, Global Product Strategy Kavita Patel, Lifecycle Leader SMA, Global Product Strategy |
Webinar Replay
Investors